Log in

Relevant bibliographies by topics / American Medical Association. Annual Meeting (27th : 6 June 1876 : Philadelphia, Pa.)

Contents

Journal articles

Academic literature on the topic 'American Medical Association. Annual Meeting (27th : 6 June 1876 : Philadelphia, Pa.)'

Author: Grafiati

Published: 29 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'American Medical Association. Annual Meeting (27th : 6 June 1876 : Philadelphia, Pa.).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "American Medical Association. Annual Meeting (27th : 6 June 1876 : Philadelphia, Pa.)"

1

Phillips, William J., Michelle Pradier, David J. Stewart, and Sara Moore. "Abstract 4623: The relationship of KRAS mutation and clinical outcomes in patients treated with consolidation durvalumab for locally advanced non-small cell lung cancer." Cancer Research 85, no. 8_Supplement_1 (2025): 4623. https://doi.org/10.1158/1538-7445.am2025-4623.

Full text

Abstract:

Introduction: KRAS G12C is associated with a favorable response to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC), while other KRAS variants show mixed effects. In addition, there is little known on how KRAS mutations affect immunotherapy responsiveness in the curative setting. This study aims to evaluate the impact of KRAS mutations on clinical outcomes of patients treated with consolidation durvalumab for unresected locally advanced NSCLC. Methods: Clinical data were gathered from the medical records of patients seen at The Ottawa Hospital Cancer Centre from June

APA, Harvard, Vancouver, ISO, and other styles

2

Ueki, Michiko, Kousuke Watanabe, Momoko Morishita, et al. "Abstract 6460: Incidence of pathogenic germline variants and presumed germline pathogenic variants in Japanese lung cancer patients using comprehensive genomic profiling tests." Cancer Research 84, no. 6_Supplement (2024): 6460. http://dx.doi.org/10.1158/1538-7445.am2024-6460.

Full text

Abstract:

Abstract Introduction: Pathogenic germline variants (PGVs) and presumed germline pathogenic variants (PGPVs) are often detected with comprehensive genomic profiling (CGP) tests. Using the Center for Advanced Cancer Genomics and Therapeutics (C-CAT) database, we investigated the incidence of PGV and PGPV detected by CGP tests in Japanese lung cancer patients. Methods: Among 3,240 lung cancer cases registered in C-CAT between June 2019 and August 2023, 321 were tumor/normal paired NCC Oncopanel (NOP), 773 were FoundationOne Liquid CDx (F1L), and 2,145 were tumor-only FoundationOne CDx (F1CDx). W

APA, Harvard, Vancouver, ISO, and other styles

3

Oda, Katsutoshi, Hidenori Kage, Manabu Muto, et al. "Abstract 3225: Real-world surveillance from cancer patients about their experience of comprehensive genomic profiling tests in Japan." Cancer Research 83, no. 7_Supplement (2023): 3225. http://dx.doi.org/10.1158/1538-7445.am2023-3225.

Full text

Abstract:

Abstract Introduction: Over 40,000 cancer patients have taken comprehensive genomic profiling (CGP) tests under health insurance coverage in Japan since June 2019. However, the indication is limited only to cancer patients who have finished (or are expected to finish) standard treatments. The aim of this study is to evaluate patients’ outcomes, levels of understanding, and satisfaction of the patients who received CGP tests. Methods: We performed a nationwide surveillance of 933 cancer patients who examined CGP tests at 80 institutions in Japan under the approval of the institutional ethics co

APA, Harvard, Vancouver, ISO, and other styles

4

Iams, Wade, Kimberly Le, Nicole Princic, Isabelle Winer, and Taylor Marlin. "Abstract 942: Real-world demographics, baseline characteristics, healthcare resource utilization and costs amongst non-small cell lung cancer (NSCLC) patients tested with a Host Immune Classifier (HIC)." Cancer Research 83, no. 7_Supplement (2023): 942. http://dx.doi.org/10.1158/1538-7445.am2023-942.

Full text

Abstract:

Abstract Background: The Host Immune Classifier is a proteomic test that identifies a chronic inflammatory disease state for patients diagnosed with NSCLC. The test stratifies patients into two groups, HIC-H and HIC-C and helps evaluate patient prognosis and response to treatment. While much work has been done to evaluate the clinical validity of the HIC test, to date, no recent real-world studies have described healthcare resource utilization (HCRU) and costs amongst patients utilizing the test. This subset analysis of HIC claims examined demographic and baseline clinical characteristics amon

APA, Harvard, Vancouver, ISO, and other styles

5

Hsu, Robert C., Darin Poei, Jacob S. Thomas, and Jorge J. Nieva. "Abstract 6111: Real world incidence of ALK alterations in Hispanic NSCLC patients in Los Angeles." Cancer Research 84, no. 6_Supplement (2024): 6111. http://dx.doi.org/10.1158/1538-7445.am2024-6111.

Full text

Abstract:

Abstract Introduction: Race and ethnicity affect the distribution of molecular alterations seen in populations of lung cancer patients. ALK fusions occur in 4-5% of non-small cell lung cancer (NSCLC) patients overall. We characterized ALK alteration presence in NSCLC Hispanics treated at a large academic institution in Los Angeles. Methods: 607 NSCLC patients treated at Los Angeles General Medical Center (LAGMC) (n=174) and Norris Comprehensive Cancer Center (NCCC) (n=433) who received comprehensive genomic profiling (CGP) were evaluated from July 2017 to June 2023. Fisher’s exact test was don

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!